Lv11
10 积分 2024-08-31 加入
The immunological and metabolic landscape in primary and metastatic liver cancer
2小时前
已完结
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2个月前
已完结
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
2个月前
已完结
The role of the gut microbiota in sepsis
2个月前
已完结
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial
2个月前
已完结
Antibiotic perturbations to the gut microbiome
2个月前
已完结
皖公网安备34019202002308
